Status:
COMPLETED
Allogeneic Umbilical Cord Blood Therapy for Stroke
Lead Sponsor:
MinYoung Kim, M.D.
Conditions:
Stroke
Eligibility:
All Genders
Phase:
PHASE1
Brief Summary
This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood (UCB) therapy for patients with stroke.
Detailed Description
Stroke is one of the most common etiologies causing disability in developed countries. There remains no proven treatments except tissue plasminogen activator currently. Based on promising results of c...
Eligibility Criteria
Inclusion
- Ischemic or hemorrhagic stroke
- Onset duration over 12 months
- Hemisphere lesions except brain stem and cerebellar lesions
- National Institute Health Stroke Scale: 10 to 15
Exclusion
- Possibility of hypersensitivity drugs used in this study
- Uncontrolled hypertension or cardiovascualr diseases
- Malignant cancer
- Renal or hepatic dysfunction (Consultation to specialist in nephrology or gastroenterology in case of renal or hepatic dysfunction)
- Severe pulmonary dysfunction
- Traumatic brain injury
- Lack of matched UCB
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01884155
Start Date
June 1 2013
End Date
December 1 2015
Last Update
October 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHA Bundang Medical Center, CHA University
Seongnam-si, Gyeonggi-do, South Korea, 463-712